Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

AVEO $1.90 0.4801 +33.81%
CALA $15.12 1.8100 +13.60%
FATE $5.38 0.3000 +5.91%
VSTM $8.42 0.4300 +5.38%
ADXS $11.54 0.4400 +3.96%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

BLRX $2.18 -0.6299 -22.42%
ONCY $0.95 -0.0999 -9.51%
GERN $3.58 -0.1970 -5.21%
EPZM $23.19 -1.2200 -5.00%
INFI $15.76 -0.7500 -4.54%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

MD Anderson President Named as Fellow of Top Cancer Research Group

(MD Anderson) Feb 18, 2015 - Ron DePinho will be inducted as a new fellow of the American Association for Cancer Research Academy.
read press release 

PCMH Model Narrowed Economic Gap for Cancer Screening

(Medscape Medical News) Feb 18, 2015 - Patient-centered medical homes (PCMHs) may raise cancer screening rates, especially among groups of lower socioeconomic status, researchers have found.
read article (free registration required) 

Association of Community Cancer Centers Commends New Oncology Care Model as a Step in the Right Direction

(ACCC) Feb 18, 2015 - Last week the Center for Medicare and Medicaid Innovation (CMMI) at the Centers for Medicare & Medicaid Services (CMS) announced its much-anticipated Oncology Care Model (OCM), a new voluntary program for physician–led practices to test the bundling of payments for chemotherapy administration. The OCM is the second specialty care model to be announced at CMMI, and the first in oncology care.
read press release 

OncoSec Medical Inc. and Heat Biologics, Inc. Announce Collaboration to Evaluate Combination of Immunotherapy Platforms

(MarketWatch) Feb 18, 2015 - OncoSec Medical Inc., a company developing DNA-based intratumoral cancer immunotherapies, and Heat Biologics, Inc., a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that they have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company.
read article 

Oncolytics Biotech® Inc. Announces Completion Of Enrollment In Randomized Phase II Colorectal Cancer Study

(TheStreet) Feb 18, 2015 - Oncolytics Biotech® Inc. today announced that enrollment has been completed in a randomized Phase II study of REOLYSIN® in patients with advanced or metastatic colorectal cancer (IND 210).
read article 

HPV Cancers in Men Take Off

(Scientific American) Feb 17, 2015 - A male-centric vaccination approach might be more effective at combating the STD.
read article 

New Research Shows High Value of Additional PET/CT Scans in Follow-Up of Lung Cancer Patients

(SNMMI) Feb 18, 2015) – New research from Johns Hopkins School of Medicine reveals a high value of scans which could lead to future change of reimbursement policies for follow-up positron emission tomography/computed tomography (PET/CT) studies in lung cancer.
read press release 

Even for Tiny Lumps, More Women Are Choosing Double Mastectomy

(Washington Post) Feb 17, 2015 – Breast surgeons have recently seen a surge in patients with small nonaggressive tumors who opt to have one or both breasts removed (including the one that’s cancer-free) rather than removing just the malignant lump in one, called a lumpectomy.
read article (free registration required) 

Study Identifies Promising Drug Target in Certain Breast and Ovarian Cancers

(Dana-Farber) Feb 13, 2015 - Study by Dana-Farber Cancer Institute scientists indicates that the pool of patients who can benefit from the drug olaparib is potentially much wider – and offers a ready means of identifying them.
read press release 

New Study Reveals How to Improve Chemotherapy Use in Prostate Cancer

(Thomas Jefferson University) Feb 17, 2015 - Next generation chemotherapy for prostate cancer has unique properties that could make it more effective earlier in treatment if confirmed in clinical trials.
read press release 

A Quarter of Thyroid Cancer Patients Receive Unnecessary RAI

(Medscape Medical News) Feb 18, 2015 - The use of radioactive iodine (RAI) in patients with thyroid cancer has decreased, but up to one-quarter of patients might still receive it unnecessarily.
read article (free registration required) 

Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS® (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at High Risk of Relapse

(Seattle Genetics) Feb 18, 2015 - Seattle Genetics, Inc. announced today that it has submitted a supplemental Biologics License Application (BLA) to the FDA based on data from the phase 3 AETHERA trial of ADCETRIS (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplant (ASCT) in Hodgkin lymphoma (HL) patients at high risk of relapse.
read corporate press release 

New Research Provides a ‘Movie’ of the Human Genome

(Boston Globe) Feb 18, 2015 - Boston scientists have developed a technique that can trace a cancer cell back to the tissue where it started, raising hope for one day improving treatment for mysterious cancers of unknown origin.
read article (paid subscription required) 

FDA Approves New Use for Celgene's Cancer Drug Revlimid

(Reuters) Feb 18, 2015 - The U.S. Food and Drug Administration has expanded the authorized use of Celgene Corp's cancer drug Revlimid to include newly diagnosed patients with multiple myeloma, the company said on Wednesday.
read article 

Up to 14 Years of Hot Flashes Found in Menopause Study

(New York Times) Feb 17, 2015 - The median length of time women endured symptoms was 7.4 years, according to researchers in the largest examination to date of the menopausal symptom.
read article 

Bayer’s Brandicourt Said to Be a Frontrunner for Sanofi CEO Post

(Bloomberg) Feb 13, 2015 - Olivier Brandicourt, who runs Bayer AG’s health-care business, is a frontrunner to become chief executive officer of Sanofi as France’s biggest drugmaker moves toward appointing a new leader by March, people with knowledge of the company’s strategy said.
read article 

CVS Joins Express Scripts in Targeting New Cholesterol Drugs

(Bloomberg) Feb 17, 2015 - CVS Health Corp., the second-biggest manager of prescription drug benefits in the U.S., will make a new class of injectable cholesterol treatments its next major target to push back against high drug costs.
read article 

Kimmel Cancer Center Appoints Director of Thoracic Oncology

(Healio) Feb 16, 2015 - Julie Brahmer, MD, a medical oncologist with extensive experience in the use of immunotherapies to treat lung cancer, has been named director of the thoracic oncology program at the Johns Hopkins Kimmel Cancer Center.
read article 

Arizona Oncology Expands Flagstaff Practice to Meet Growing Demand for Services in Northern Arizona

(The US Oncology Network) Feb 16, 2015 - Arizona Oncology, a practice in The US Oncology Network, has expanded its Flagstaff clinic location to meet the growing demand for cancer treatment services in Northern Arizona.
read corporate press release 

Fresenius Kabi Sells German Oncology Compounding Business

(Reuters) Feb 16, 2015 - Fresenius Kabi has sold its German oncology business CFL GmbH to fellow compounding company NewCo Pharma GmbH for an undisclosed amount, the company said on Monday.
read article 

Ignyta Receives Orphan Drug Designation from FDA for Entrectinib for the Treatment of Molecularly Defined Subsets of Colorectal Cancer

(Ignyta) Feb 17, 2015 - Ignyta, Inc., a precision oncology biotechnology company, today announced that the FDA has granted orphan drug designation for Ignyta’s lead product candidate entrectinib for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive or ALK-positive colorectal cancer.
read corporate press release 

Oncolytics Biotech® Inc. Announces Receipt of Orphan Drug Designation from the U.S. FDA for Pancreatic Cancer

(Yahoo! Finance) Feb 17, 2015 - Oncolytics Biotech® Inc. today announced that the FDA has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer.
read article 

VBL Therapeutics Announces Removal of FDA Partial Clinical Hold on VB-111

(TheStreet) Feb 17, 2015 - VBL Therapeutics today announced that the FDA has determined that VBL may proceed with its pivotal Phase 3 trial in patients with recurrent glioblastoma (rGBM) and removed the clinical hold on the trial, allowing the trial to proceed under a previously agreed upon special protocol assessment (SPA).
read article 

Dako, an Agilent Technologies Company, and ONO Pharmaceutical Co., Ltd. Announce Collaboration on Development of PD-L1 Companion Diagnostic Test for Investigational Cancer Drug Opdivo® (nivolumab)

(NASDAQ) Feb 16, 2015 - Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Ono Pharmaceutical Co., Ltd., today announced a new partnership to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer (NSCLC).
read article 

Research Funding, SGR Center Stage During ASCO Capitol Hill Visits

(ASCO in Action) Feb 13, 2015 - As the 114th Congress gets underway, ASCO volunteers yesterday came to Capitol Hill to advocate on cancer policy issues that will be front-and-center this year.
read article